Olmesartan
Amlodipine Besylate / Hydrochlorothiazide / Olmesartan Medoxomil, Amlodipine Besylate / Olmesartan Medoxomil, Azor, Benicar, Hydrochlorothiazide / Olmesartan Medoxomil, Olmesartan Medoxomil, Tribenzor (olmesartan) is a small molecule pharmaceutical. Olmesartan was first approved as Benicar on 2002-04-25. It is used to treat diabetic nephropathies, heart failure, hypertension, and left ventricular dysfunction in the USA. The pharmaceutical is active against type-1 angiotensin II receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| amlodipine and olmesartan medoxomil | ANDA | 2024-08-15 |
| amlodipine besylate and olmesartan medoxomil | New Drug Application | 2024-06-03 |
| azor | New Drug Application | 2023-07-12 |
| benicar | New Drug Application | 2023-07-12 |
| benicar hct | New Drug Application | 2023-07-12 |
| olmesartan medoxomil | ANDA | 2024-10-31 |
| olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide | ANDA | 2024-11-06 |
| olmesartan medoxomil and hydrochlorothiazide | ANDA | 2024-10-04 |
| olmesartan medoxomil, amlodipine and hydrochlorothiazide | ANDA | 2021-01-31 |
| olmesartan medoxomil, amlodipine and hydrochlorothiazide 20/5/12.5 mg | ANDA | 2017-03-16 |
Show 3 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C09: Agents acting on the renin-angiotensin system
— C09C: Angiotensin ii receptor blockers (arbs), plain
— C09CA: Angiotensin ii receptor blockers (arbs), plain
— C09CA08: Olmesartan medoxomil
— C09D: Angiotensin ii receptor blockers (arbs), combinations
— C09DA: Angiotensin ii receptor blockers (arbs) and diuretics
— C09DA08: Olmesartan medoxomil and diuretics
— C09DB: Angiotensin ii receptor blockers (arbs) and calcium channel blockers
— C09DB02: Olmesartan medoxomil and amlodipine
— C09DX: Angiotensin ii receptor blockers (arbs), other combinations
— C09DX03: Olmesartan medoxomil, amlodipine and hydrochlorothiazide
HCPCS
No data
Clinical
Clinical Trials
159 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 8 | 45 | 35 | 18 | 106 |
| Essential hypertension | D000075222 | — | I10 | — | 2 | 29 | 8 | 4 | 43 |
| Healthy volunteers/patients | — | — | — | 16 | — | 1 | 1 | — | 18 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | 4 | 3 | 1 | 9 |
| Dyslipidemias | D050171 | HP_0003119 | — | — | — | 2 | 2 | 2 | 6 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | 2 | 3 | 1 | 6 |
| Covid-19 | D000086382 | — | — | — | — | 2 | 2 | 1 | 5 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 3 | 2 | — | 5 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | 3 | 2 | — | 5 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 2 | — | 2 | — | 4 |
Show 21 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | HP_0001635 | I50 | — | — | 2 | — | 1 | 3 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | 1 | 2 | — | — | 3 |
| Hyperlipidemias | D006949 | HP_0003077 | E78.5 | — | — | 1 | — | 1 | 2 |
| Syndrome | D013577 | — | — | — | — | 2 | — | — | 2 |
| Proteinuria | D011507 | HP_0000093 | R80 | — | — | 2 | — | — | 2 |
| Infections | D007239 | EFO_0000544 | — | — | — | 1 | — | — | 1 |
| Severe acute respiratory syndrome | D045169 | EFO_0000694 | J12.81 | — | — | 1 | — | — | 1 |
| Communicable diseases | D003141 | — | — | — | — | 1 | — | — | 1 |
| Pneumonia | D011014 | EFO_0003106 | — | — | — | 1 | — | — | 1 |
| Hyperlipoproteinemias | D006951 | HP_0010980 | — | — | — | 1 | — | — | 1 |
Show 9 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ischemic stroke | D000083242 | — | — | — | 2 | — | — | — | 2 |
| Ischemia | D007511 | EFO_0000556 | — | — | 2 | — | — | — | 2 |
| Cerebral infarction | D002544 | — | I63 | — | 1 | — | — | — | 1 |
| Coronary disease | D003327 | — | — | — | 1 | — | — | — | 1 |
| Glomerulonephritis | D005921 | HP_0000099 | N05 | — | 1 | — | — | — | 1 |
| Chronic disease | D002908 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Systolic heart failure | D054143 | EFO_1001207 | I50.20 | — | — | — | — | 1 | 1 |
| Frailty | D000073496 | — | R53.1 | — | — | — | — | 1 | 1 |
| Hyperaldosteronism | D006929 | HP_0011736 | E26 | — | — | — | — | 1 | 1 |
| Adenoma | D000236 | — | — | — | — | — | — | 1 | 1 |
| Ambulatory blood pressure monitoring | D018660 | — | — | — | — | — | — | 1 | 1 |
| Vascular stiffness | D059289 | — | — | — | — | — | — | 1 | 1 |
| Exercise | D015444 | EFO_0000483 | — | — | — | — | — | 1 | 1 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | — | — | — | 1 | 1 |
| Sleep apnea syndromes | D012891 | HP_0010535 | G47.3 | — | — | — | — | 1 | 1 |
| Apnea | D001049 | HP_0002104 | R06.81 | — | — | — | — | 1 | 1 |
Show 10 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Olmesartan |
| INN | olmesartan |
| Description | Olmesartan medoxomil is a member of biphenyls. |
| Classification | Small molecule |
| Drug class | angiotensin II receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 144689-24-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1516 |
| ChEBI ID | 48416 |
| PubChem CID | 130881 |
| DrugBank | DB00275 |
| UNII ID | 8W1IQP3U10 (ChemIDplus, GSRS) |
Target
Agency Approved
AGTR1
AGTR1
Organism
Homo sapiens
Gene name
AGTR1
Gene synonyms
AGTR1A, AGTR1B, AT2R1, AT2R1B
NCBI Gene ID
Protein name
type-1 angiotensin II receptor
Protein synonyms
Angiotensin II type-1 receptor, AT1 receptor, AT1AR, AT1BR, type-1B angiotensin II receptor
Uniprot ID
Mouse ortholog
Agtr1b (11608)
type-1 angiotensin II receptor B (P29755)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Olmesartan
+
Amlodipine
+
Hydrochlorothiazide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Olmesartan
+
Amlodipine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Olmesartan
+
Hydrochlorothiazide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Olmesartan
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,278 documents
View more details
Safety
Black-box Warning
Black-box warning for: Amlodipine and olmesartan medoxomil, Amlodipine besylate and olmesartan medoxomil, Azor, Benicar, Benicar hct, Olmesartan medoxomil, Olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide, Olmesartan medoxomil and hydrochlorothiazide, Olmesartan medoxomil, amlodipine and hydrochlorothiazide, Olmesartan medoxomil, amlodipine and hydrochlorothiazide 20/5/12.5 mg, Olmesartan medoxomil, amlodipine and hydrochlorothiazide 20/5/12.5 mg olmesartan medoxomil, amlodipine and hydrochlorothiazide 40/10/12.5 mg olmesa..., Olmesartan medoxomil-hydrochlorothiazide, Tribenzor
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
25,267 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use